Immune suppressive mechanisms in the tumor microenvironment

Postow, 2015, Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030 Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498 Van Allen, 2015, Genomic correlates of response to CTLA4 blockade in metastatic melanoma, Science, 350, 207, 10.1126/science.aad0095 Kvistborg, 2014, Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response, Sci Transl Med, 6, 254ra128, 10.1126/scitranslmed.3008918 Walker, 2015, Confusing signals: recent progress in CTLA-4 biology, Trends Immunol, 36, 63, 10.1016/j.it.2014.12.001 Simpson, 2013, Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma, J Exp Med, 210, 1695, 10.1084/jem.20130579 Bauer, 2014, Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction, J Clin Invest, 124, 2425, 10.1172/JCI66375 Joshi, 2015, Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses, Immunity, 43, 579, 10.1016/j.immuni.2015.08.006 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Spranger, 2013, Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells, Sci Transl Med, 5, 200ra116, 10.1126/scitranslmed.3006504 Balkwill, 2001, Inflammation and cancer: back to Virchow?, Lancet, 357, 539, 10.1016/S0140-6736(00)04046-0 Schafer, 2008, Cancer as an overhealing wound: an old hypothesis revisited, Nat Rev Molec Cell Biol, 9, 628, 10.1038/nrm2455 Rybinski, 2014, The wound healing, chronic fibrosis, and cancer progression triad, Physiol Genomics, 46, 223, 10.1152/physiolgenomics.00158.2013 Mantovani, 2013, Macrophage plasticity and polarization in tissue repair and remodelling, J Pathol, 229, 176, 10.1002/path.4133 Motz, 2011, The parallel lives of angiogenesis and immunosuppression: cancer and other tales, Nat Rev Immunol, 11, 702, 10.1038/nri3064 Franklin, 2014, The cellular and molecular origin of tumor-associated macrophages, Science, 344, 921, 10.1126/science.1252510 Ugel, 2015, Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages, J Clin Invest, 125, 3365, 10.1172/JCI80006 Colegio, 2014, Functional polarization of tumour-associated macrophages by tumour-derived lactic acid, Nature, 513, 559, 10.1038/nature13490 Mitchem, 2013, Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses, Cancer Res, 73, 1128, 10.1158/0008-5472.CAN-12-2731 Ries, 2014, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy, Cancer Cell, 25, 846, 10.1016/j.ccr.2014.05.016 Marigo, 2010, Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor, Immunity, 32, 790, 10.1016/j.immuni.2010.05.010 Thevenot, 2014, The stress-response sensor CHOP regulates the function and accumulation of myeloid-derived suppressor cells in tumors, Immunity, 41, 389, 10.1016/j.immuni.2014.08.015 Holmgaard, 2015, Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner, Cell Rep, 13, 412, 10.1016/j.celrep.2015.08.077 Marvel, 2015, Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected, J Clin Invest, 125, 3356, 10.1172/JCI80005 Goldszmid, 2014, Host immune response to infection and cancer: unexpected commonalities, Cell Host Microbe, 15, 295, 10.1016/j.chom.2014.02.003 Broz, 2014, Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity, Cancer Cell, 26, 638, 10.1016/j.ccell.2014.09.007 Kerkar, 2011, IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors, J Clin Invest, 121, 4746, 10.1172/JCI58814 Ma, 2013, Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells, Immunity, 38, 729, 10.1016/j.immuni.2013.03.003 Spranger, 2015, Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity, Nature, 523, 231, 10.1038/nature14404 Munn, 2013, Indoleamine 2,3 dioxygenase and metabolic control of immune responses, Trends Immunol, 34, 137, 10.1016/j.it.2012.10.001 Ravishankar, 2012, Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase, Proc Natl Acad Sci USA, 109, 3909, 10.1073/pnas.1117736109 Munn, 2005, GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase, Immunity, 22, 633, 10.1016/j.immuni.2005.03.013 Mezrich, 2010, An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells, J Immunol, 185, 3190, 10.4049/jimmunol.0903670 Holmgaard, 2013, Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4, J Exp Med, 210, 1389, 10.1084/jem.20130066 Wainwright, 2014, Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors, Clin Cancer Res, 20, 5290, 10.1158/1078-0432.CCR-14-0514 Spranger, 2014, Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment, J Immunother Cancer (JITC), 2, 3, 10.1186/2051-1426-2-3 Ninomiya, 2015, Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs, Blood, 125, 3905, 10.1182/blood-2015-01-621474 Huang, 2013, Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses, J Immunol, 191, 3509, 10.4049/jimmunol.1301419 Nishikawa, 2014, Regulatory T cells in cancer immunotherapy, Curr Opin Immunol, 27, 1, 10.1016/j.coi.2013.12.005 Bos, 2013, Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy, J Exp Med, 210, 2435, 10.1084/jem.20130762 Ali, 2014, Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer, Nature, 510, 407, 10.1038/nature13444 Malchow, 2013, Aire-dependent thymic development of tumor-associated regulatory T cells, Science, 339, 1219, 10.1126/science.1233913 Sharma, 2007, Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase, J Clin Invest, 117, 2570, 10.1172/JCI31911 Delgoffe, 2013, Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis, Nature, 501, 252, 10.1038/nature12428 Sharma, 2015, The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment, Sci Adv, 1, e1500845, 10.1126/sciadv.1500845 Huynh, 2015, Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability, Nat Immunol, 16, 188, 10.1038/ni.3077 Shrestha, 2015, Treg cells require the phosphatase PTEN to restrain Th1 and Tfh cell responses, Nat Immunol, 16, 178, 10.1038/ni.3076 Bezu, 2015, Combinatorial strategies for the induction of immunogenic cell death, Front Immunol, 6, 187 Poon, 2014, Apoptotic cell clearance: basic biology and therapeutic potential, Nat Rev Immunol, 14, 166, 10.1038/nri3607 Liu, 2015, CD47 blockade triggers T cell-mediated destruction of immunogenic tumors, Nat Med, 21, 1209, 10.1038/nm.3931 Shalapour, 2015, Immunity, inflammation, and cancer: an eternal fight between good and evil, J Clin Invest, 125, 3347, 10.1172/JCI80007 Gentles, 2015, The prognostic landscape of genes and infiltrating immune cells across human cancers, Nat Med, 21, 938, 10.1038/nm.3909